1 | Acetate | 1件: Acetate Acetate | - | - | - | 41件: 1 1, 2, 6, 10, 13, 46, 49, 51, 60, 64, 67, 70, 71, 73, 75, 76, 78, 79, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 171, 206, 222, 224, 225, 227, 235, 251, 265, 288, 298, 299 |
2 | ALX-0081 | - | - | - | - | 1件: 64 64 |
3 | ALX0081 | - | - | - | - | 1件: 64 64 |
4 | Anfibatide | 1件: Anfibatide Anfibatide | - | - | - | 1件: 64 64 |
5 | Anti-CD20 antibody | - | - | - | - | 1件: 64 64 |
6 | Anti-von Willebrand Factor Nanobody | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 64 64 |
7 | Anti-von Willebrand Factor Nanobody, Caplacizumab | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: D11160
D11160
| 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 |
8 | Anti-von Willebrand Factor Nanobody, INN = Caplacizumab | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: D11160
D11160
| 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 |
9 | Apadamtase alfa | 1件: Apadamtase alfa Apadamtase alfa | - | - | - | 1件: 64 64 |
10 | Apademtase alfa | - | - | - | - | 1件: 64 64 |
11 | ARC 1779 | - | - | - | - | 2件: 64 64, 288 |
12 | ARC1779 | - | - | - | - | 2件: 64 64, 288 |
13 | ARC1779 Injection | - | - | - | - | 2件: 64 64, 288 |
14 | Aspirin | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: D00109
D00109
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 12件: 13 13, 22, 46, 49, 51, 58, 64, 86, 113, 158, 210, 231 |
15 | Aspirin tablet | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: D00109
D00109
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 64 64 |
16 | BAX930 | - | - | - | - | 1件: 64 64 |
17 | BAX930 - RECOMBINANT HUMAN ADAMTS13 | - | - | - | - | 1件: 64 64 |
18 | BAX930 or SHP655 | - | - | - | - | 1件: 64 64 |
19 | BAX930 or SHP655 or TAK755 | - | - | - | - | 1件: 64 64 |
20 | BORTEZOMIB | 1件: Bortezomib Bortezomib | 1件: D03150
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 17件: 11 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 222, 228, 256, 283, 288, 331 |
21 | Bortezomib Injection | 1件: Bortezomib Bortezomib | 1件: D03150
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 64 64 |
22 | CABLIVI | 1件: Caplacizumab Caplacizumab | 1件: D11160
D11160
| 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 |
23 | Cablivi® | 1件: Caplacizumab Caplacizumab | 1件: D11160
D11160
| 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 |
24 | CAPLACIZUMAB | 1件: Caplacizumab Caplacizumab | 1件: D11160
D11160
| 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 |
25 | Caplacizumab (ALX-0081) | 1件: Caplacizumab Caplacizumab | 1件: D11160
D11160
| 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 |
26 | Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: D11160
D11160
| 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 |
27 | Caplacizumab (an anti-von Willebrand Factor Nanobody) | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: D11160
D11160
| 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 |
28 | Corticosteroid treatment (Methylprednisolone or prednisolone) | 2件: Methylprednisolone Methylprednisolone, Prednisolone | 2件: D00407
D00407
,
D00472
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 64 64 |
29 | Corticosteroids | - | - | - | - | 12件: 41 41, 46, 49, 63, 64, 97, 107, 113, 164, 220, 296, 300 |
30 | Cryosupernatant plasma | - | - | - | - | 1件: 64 64 |
31 | Cyclosporine | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 37件: 11 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 107, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
32 | Danazol | 1件: Danazol Danazol | 1件: D00289
D00289
| 3件: AR AR, ESR1, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 5件: 60 60, 63, 64, 65, 285 |
33 | Desmopressin | 1件: Desmopressin Desmopressin | 1件: D00291
D00291
| 2件: AVPR2 AVPR2, F8 💬 | 4件: Complement and coagulation cascades Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 5件: 6 6, 64, 72, 225, 288 |
34 | Desmopressin acetate | 2件: Acetate Acetate, Desmopressin | 1件: D00291
D00291
| 2件: AVPR2 AVPR2, F8 💬 | 4件: Complement and coagulation cascades Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 2件: 64 64, 288 |
35 | Dexamethasone | 1件: Dexamethasone Dexamethasone | 1件: D00292
D00292
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 22件: 13 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 81, 84, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
36 | HMED-IdeS | 1件: Imlifidase Imlifidase | 1件: D11470
D11470
| - | - | 2件: 64 64, 221 |
37 | IDEC-C2B8, Ro 45-2294 | - | - | - | - | 1件: 64 64 |
38 | IdeS | 1件: Imlifidase Imlifidase | 1件: D11470
D11470
| - | - | 2件: 64 64, 221 |
39 | IdeS (0.25 mg/kg) | 1件: Imlifidase Imlifidase | 1件: D11470
D11470
| - | - | 1件: 64 64 |
40 | IdeS (0.50 mg/kg) | 1件: Imlifidase Imlifidase | 1件: D11470
D11470
| - | - | 1件: 64 64 |
41 | Immunosuppressive treatment (eg, rituximab) | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 64 64 |
42 | MabThera | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 22件: 11 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271 |
43 | Magnesium | 1件: Magnesium Magnesium | - | - | - | 15件: 6 6, 11, 46, 64, 70, 93, 97, 166, 225, 235, 284, 291, 296, 297, 298 |
44 | MASP-2 antibody | 1件: Narsoplimab Narsoplimab | 1件: D11531
D11531
| 1件: MASP2 MASP2 💬 | 3件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬 | 3件: 64 64, 66, 109 |
45 | Methylprednisolone | 1件: Methylprednisolone Methylprednisolone | 1件: D00407
D00407
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 46件: 2 2, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 |
46 | Minirin | 1件: Desmopressin Desmopressin | 1件: D00291
D00291
| 2件: AVPR2 AVPR2, F8 💬 | 4件: Complement and coagulation cascades Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 2件: 64 64, 288 |
47 | Nanobody directed towards the human A1 domain of von Willebrand factor | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 64 64 |
48 | Octaplas | 1件: Plasma protein fraction (human) Plasma protein fraction (human) | - | - | - | 1件: 64 64 |
49 | Octaplas infusion | 1件: Plasma protein fraction (human) Plasma protein fraction (human) | - | - | - | 1件: 64 64 |
50 | Octaplas SD | 1件: Plasma protein fraction (human) Plasma protein fraction (human) | - | - | - | 1件: 64 64 |
51 | OctaplasLG® | - | - | - | - | 1件: 64 64 |
52 | Octaplas®LG | 1件: Plasma protein fraction (human) Plasma protein fraction (human) | - | - | - | 1件: 64 64 |
53 | Octostim | - | - | - | - | 2件: 64 64, 288 |
54 | OMS721 | - | - | - | - | 3件: 64 64, 66, 109 |
55 | OMS721 100 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody | 1件: Narsoplimab Narsoplimab | 1件: D11531
D11531
| 1件: MASP2 MASP2 💬 | 3件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬 | 2件: 64 64, 109 |
56 | OMS721 185 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody | 1件: Narsoplimab Narsoplimab | 1件: D11531
D11531
| 1件: MASP2 MASP2 💬 | 3件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬 | 2件: 64 64, 109 |
57 | Plasma exchange (PE) | - | - | - | - | 1件: 64 64 |
58 | Pooled Plasma (Human), Solvent/Detergent Treated | - | - | - | - | 1件: 64 64 |
59 | PREDNISOLONE | 1件: Prednisolone Prednisolone | 1件: D00472
D00472
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 42件: 3 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
60 | Prednisone | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 45件: 2 2, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331 |
61 | RADAMTS-13 | - | - | - | - | 1件: 64 64 |
62 | Recombinant A Disintegrin and Metalloproteinase Thrombospondin Type-1 Motifs 13 | - | - | - | - | 1件: 64 64 |
63 | Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 | - | - | - | - | 1件: 64 64 |
64 | Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs | - | - | - | - | 1件: 64 64 |
65 | Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs 13 | - | - | - | - | 1件: 64 64 |
66 | Recombinant A Disintegrin And Metalloproteinase with Thrombospondin Type-1 Motifs 13 (rADAMTS13) | - | - | - | - | 1件: 64 64 |
67 | Recombinant ADAMTS13 | - | - | - | - | 1件: 64 64 |
68 | RITUXIMAB | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 48件: 11 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |
69 | Romiplostim | 1件: Romiplostim Romiplostim | 1件: D08990
D08990
| 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 4件: 60 60, 63, 64, 65 |
70 | SHP 655 (BAX 930) | - | - | - | - | 1件: 64 64 |
71 | SHP655 | - | - | - | - | 1件: 64 64 |
72 | Standard of Care | - | - | - | - | 8件: 6 6, 13, 49, 51, 63, 64, 79, 171 |
73 | Standard Plasma | - | - | - | - | 1件: 64 64 |
74 | Standrd of Care treatment | - | - | - | - | 1件: 64 64 |
75 | Sulfate | 1件: Sulfate ion Sulfate ion | - | - | - | 27件: 2 2, 3, 6, 11, 13, 26, 28, 34, 36, 46, 49, 53, 60, 64, 66, 85, 86, 96, 111, 218, 222, 224, 226, 265, 296, 297, 299 |
76 | Sulfate, Magnesium | 2件: Magnesium Magnesium, Sulfate ion | - | - | - | 1件: 64 64 |
77 | TAK-755 | - | - | - | - | 1件: 64 64 |
78 | TAK-755 or BAX930 or SHP655 | - | - | - | - | 1件: 64 64 |
79 | TAK-755 orBAX930 or SHP655 | - | - | - | - | 1件: 64 64 |
80 | Uniplas | - | - | - | - | 1件: 64 64 |
81 | Von willebrand factor | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 2件: 64 64, 288 |